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Abstract
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University- Minnesota State University Mankato MN56001
Year- 2017

Proteins containing polyglutamine (polyQ) tracts within their primary amino acid
sequence are particularly interesting because expansion mutation within them has been
shown to underlie a growing list of severe neurodegenerative disorders including
Huntington’s Disease and several types of Spinocerebellar Ataxias. FAM171B is a novel
polyQ protein that was originally identified via large scale sequencing efforts. However,
to date, very little is known regarding its normal cellular function and expression pattern.
In this study, in situ hybridization was utilized to assess whether FAM171B is expressed
in developing (postnatal days 7, 21, 42) and adult mouse brains. The results of the
experiments performed suggest that FAM171B is indeed expressed in the brain, with
pronounced expression in the hippocampus, Purkinje cells of the cerebellum, and cerebral
cortex. Given these findings, FAM171B should be considered a candidate gene for
exploration of molecularly uncharacterized neurodegenerative diseases.
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Chapter 1
Introduction
While the human genome encodes approximately 20,000 proteins; a substantial
number of them remain uncharacterized (1). One such novel gene product is the 92kD
protein FAM171B (2). Although there is minimal published data regarding the molecular
function of FAM171B in cells, some important characteristics can be inferred from the bioinformatic analysis of its amino acid sequence. For example, FAM171B is predicted to
contain an A-T hook within its structure. Since A-T hooks are DNA binding domains,
FAM171B may therefore have a nuclear function. Additionally, FAM171B contains a
polyglutamine (polyQ) region within its primary amino acid sequence (2). PolyQ proteins
are particularly interesting, as mutations in these regions have been shown to underlie a
growing list of severe neurodegenerative disorders (3).
Polyglutamine disorders are classified by nine neurodegenerative diseases (Table
1). Severe neurodegenerative disorders such as Huntington’s Disease, several
Spinocerebellar Ataxias (SCA 1,2,3,6,7,17), Spinal-Bulbar Muscular Atrophy (SBMA),
and Dentatorubral-Pallidoluysian Atrophy (DRPLA) are all caused by mutations in polyQ
stretches within their respective gene products (3, 4) (5).

All polyQ diseases are

progressive and ultimately fatal disorders without a known cure (5). In each polyQ
disorder, the glutamine sequence, which is coded for by cysteine, adenine and guanine as
a trinucleotide (CAG) within the mRNA coding region, (8) extends well beyond its normal
range leading to specific cell loss within the brain and consequent disease (5) (6). An
interesting feature regarding this phenomenon is that the longer the polyQ stretch within
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the protein, the more severe the disease manifests -- clearly implicating the polyQ region
itself as being the toxic agent (5) (7). The damage results from the toxic gain of function
of protein aggregates due to expansion of translated CAG repeats (7) (9).
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Table1. Polyglutamine disorders with normal and mutant CAG repeats & the brain regions
that are affected (10-19).

Disease

Type of
nucleotide

Normal
Range

Mutant
range

Most affected Brain
region

Huntington’s
Disease

CAG

11-34

37-121

Caudate, Cerebral Cortex

CAG

19-36

42-81

Cerebellar Purkinje cells
brain stem

CAG

15-29

35-59

Cerebellar Purkinje cells
brain stem

CAG

12-40

66-200

Cerebellar Dentate
neurons, basal ganglia,
brain stem

CAG

4-16

21-28

Cerebellar purkinje cells,
Dentate nucleus

CAG

<64

>64

Brain stem. cerebellum

CAG

9-28

55-78

Cerebellum

CAG

29-42

47-55

Cerebellar Purkinje cells

CAG

7-34

49-83

Cerebellum, basal
ganglia, Cerebral Cortex

Spinocerebellar
Ataxia type 1
(SCA1)
Spinocerebellar
Ataxia type 2
(SCA2)
Machado-Joseph
Ataxia (SCA3)
Spinocerebellar
Ataxia Type 6
(SCA6)
Spinocerebellar
Ataxia Type 7
(SCA7)
Spinocerebellar
Ataxia Type 12
(SCA12)
Spinocerebellar
Ataxia Type 17
(SCA17)
DentatorubralPallidoluysian
Atropy (DRPLA)

Spinocerebellar ataxia type 1 (SCA1) (Table 1) is an inherited polyglutamine
neurodegenerative disorder characterized by ataxia, the loss of voluntary controlled
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coordination of muscle movements and progressive bulbar dysfunction (10). Unaffected
individuals possess ~6-39 CAG repeats within the SCA1 gene located on the short arm of
chromosome 6 (10). An affected individual, in contrast, can exhibit anywhere from 40 to
81 CAG repeats within the SCA1 gene (10).
Spinocerebellar ataxia type 2 (SCA2) (Table 1) is an autosomal dominantly
inherited neurodegenerative disorder that results from an expansion of CAG repeats within
the ATXN2 gene (11). SCA type 2 disorder, which causes damage primarily to cerebellar
purkinje cells (11), produces several symptoms, with progressive ataxia dominating.
Unaffected individuals can exhibit from 14 up to 31 CAG repeats while affected persons
are known to possess more than 32 CAG residues within the ATXN2 gene (11).
Spinocerebellar Ataxia type 3 (Table 1), also known as Machado-Joseph disease,
is the most commonly inherited Spinocerebellar ataxia. Persons diagnosed with this
disorder exhibit 61-84 CAG repeats within their MJD1 gene, resulting in neuronal
degeneration of the basal ganglia, brain stem, spinal cord and cerebellum (12). Unaffected
individuals, on the other hand, contain a much lower number (12-37) CAG repeats within
the MJD1 gene (12).
Spinocerebellar Ataxia type 6 (Table 1) primarily affects the cerebellum, in
particular the purkinje cells (13). Unaffected individuals exhibit 4-20 CAG repeats within
the SCA6 gene while the diseased gene can possess from 21 up to 33 CAG repeats (13).
Spinocerebellar Ataxia type 7 (Table 1) results in severe neuronal loss in the
inferior olivary complex as well as damage to neuronal cells of the cerebral cortex (14).
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CAG repeats within the pathological gene can vary between 37 and 200 CAG repeats
whereas in the normal SCA7 gene, there are less than 36 CAG repeats (14).
Spinocerebellar ataxia type 12 (SCA12) is a slowly progressive neurodegenerative
disorder that is dominantly inherited. Action tremors, anxiety and depression are the most
common symptoms associated with this disorder (15). SCA12 results from expansion of
the CAG repeats within the PPP2R2B gene. Unaffected individuals contain 7-28 CAG
repeats within this gene. Diseased individuals, on the other hand, can exhibit anywhere
from 55-78 CAG repeats (15) (Table 1).
Spinocerebellar Ataxia type 17 (SCA17) is characterized by ataxia, dementia and
involuntary muscle movements, resulting in chorea (uncontrollable motor dysfunction) and
dystonia (involuntary muscle movements). Patients with this disorder start to express
symptoms at mid age (16). Neuronal damage occurs mainly within the cerebellum, brain
stem and cerebrum. The TBP gene, which is affected by the number of CAG repeats
present, encodes a TATA box binding protein that is necessary for transcription to take
place (16). Unaffected individuals contain 25-40 CAG repeats within the TBP gene
whereas affected persons contain 41-48 CAG repeats within this gene (16) (Table 1).
Dentatorubral and pallidoluysian atrophy (DRPLA) is another polyglutamine
neurodegenerative disorder that is characterized by ataxia and abnormal muscle control,
but affected persons also experience tremors, seizures and even premature death. This
disease is inherited in an autosomal dominant fashion and like SCA17 occurs in middleaged individuals (17). In these persons, neuronal damage and gliosis occur in many regions
of the brain, although the Dentate nucleus of the cerebellum, the red nucleus, the Globus
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pallidus and the sub-thalamic nucleus show prominent neuronal damage (17).

In

unaffected individuals, the CAG repeat sequence within the atrophin-1 gene can vary
between 6 to 35 CAG repeats (Table 1). Meanwhile, individuals with DRPLA can possess
from 49 up to 88 CAG repeats within this gene (17).
Huntington’s disease is an autosomal dominantly inherited neurodegenerative
disorder categorized by chorea, cognitive decline, dementia and ultimately death within
15-20 years of being diagnosed (3). Interestingly, Huntington’s disease is characterized by
putative and progressive clinically irreversible symptoms involved with neural protein
aggregates (18) that are caused by polyglutamine expansion within the Huntingtin (HTT)
gene on the short arm of chromosome 4. Unaffected individuals typically contain 26 or
fewer polyglutamine repeats within the HTT gene while affected persons exhibit between
40 and ~100 CAG repeat sequences (Table 1). In the later group, the disease usually
manifests itself in mid-life but the symptoms may not appear until much later in life due to
reduced penetrance of the CAG repeat regions. It is interesting to note that as the Huntingtin
gene is passed on to the next generation from an affected parent (50% chance of
transmitting the abnormal HTT gene to his/her children (19)), the polyglutamine regions
can expand. The severity and manifestation of the disease, however, is directly dependent
on the number of CAG repeats in the HTT gene: (1) 27-35 CAG repeats – these individuals
do not exhibit Huntington’s disease but there is a high probability of them transmitting the
disease to the next generation, (2) 36-39 CAG repeats – these persons may or may not be
affected by Huntington’s disease due to reduced penetrance, and (3) ≥40 CAG repeats –
these individuals will always exhibit Huntington’s disease (19) (Table 1).
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According to Nelson et. al. (21), expansion of polyQ stretches somehow endows
proteins with a toxic gain of function that ultimately kills neurons. Even though each
polyglutamine disease is rare, as a group these are the most common form of inherited
neurodegenerative diseases (7).
Mesenchymal stem cells, also known as marrow stromal cells (MSC), have been
used as a therapeutic tool for cell therapy as well as in many clinical trials that have been
approved by the FDA (22). Myocardial infarction, strokes and autoimmune disorders are a
few of the many disorders that MSCs have been used as a tool for therapeutic advantage.
Nowadays, researchers are showing a great interest in determining whether or not MSCs
can be used to treat neurodegenerative disorders, especially diseases like Huntington’s
disease that are progressive and fatal (22). Pre-clinical trials suggest that transplantation
(via intracerebral or intrathecal injection) of mesenchymal stem cells into the brain endorse
endogenous neuronal growth, decrease apoptosis, and increase paracrine secretions that
can be used to regenerate synaptic connections of already damaged neurons and control
inflammation (22). As such, mesenchymal stem cells can provide a potential regenerative
approach for those progressive and fatal neurodegenerative disorders. Ongoing clinical
trials where MSC’s were directly injected in to the central nervous system during traumatic
brain injuries support the current hypothesis regarding the use of MSCs as a therapeutic
tool for neuronal cell regeneration in the brain (22).
Since FAM171B also includes a PolyQ stretch within its protein, it is interesting to
further investigate about this uncharacterized protein. Although it is not clear whether the
newly identified polyQ protein FAM171B will ever be linked to a particular disease, polyQ
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proteins in general are fascinating because of their common role in neurodegenerative
disease. Moreover, uncovering the normal cellular function of a novel human protein, in
this case FAM171B, is a worthwhile endeavor that will advance the field of cellular
biology. Thus, the current project was undertaken to gain insight about the novel polyQ
protein FAM171B, and specifically answer questions regarding which body tissues it is
normally expressed in. If our findings show that FAM171B is expressed in the brain, then
FAM171B could potentially be considered a candidate gene for exploring a molecularly
uncharacterized neurodegenerative disease.
The methodology that was employed to accomplish the abovementioned goal, is a
method coined in-situ hybridization. This specialized staining technique relies on Watson
and Crick base pairing between polynucleotides within its complementary RNA sequence
(23). In-situ hybridization is a standard molecular technique that harnesses the power of
nucleotide base pairing that occurs between complementary bases in RNA, to investigate
for expression of specific genes in tissues of the body. Additionally, this technique can be
highly sensitive when a targeted nucleic acid sequence is in a small percentage of cells or
in specific regions of an organ (24). In-situ hybridization is commonly used in cell biology
to localize mRNA via light microscopy (23). Hybridization products are obtained via a
phosphatase coupled antibody reaction against the degoxygenin products (25). Following
sample fixation and embedding procedures, the sample can be analyzed using
a light microscope to visualize gene expression (24). In-order-to observe and analyze the
expression of FAM171B mRNA in brain tissue, brains from mice representing four
different age groups were harvested. Mice brains were used in this study given that
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genomic sequencing data suggests that mice contain a FAM171B protein that is ~ 88%
identical in sequence to the human FAM171B protein although the number of
polyglutamine repeats does vary (16 in humans versus whereas 7 in mice) (39).

Hypothesis
In the current study, it is hypothesized that FAM171B will be expressed in the
brains of mice and that the expression may be temporally or spatially specific. To test this
hypothesis, in-situ hybridization will be performed on various regions of brain tissue
harvested from laboratory mice representing four different age groups.

Prediction
Observation of FAM171B is anticipated in the different regions of the mouse brain,
although the expression of this protein may vary between the different regions of the brain.
Expression of FAM171B is also expected to vary in a time-wise manner of the mouse life
cycle, thus we will be able to detect this time-based expression by examining the brain
tissue of mice belonging to different age groups.
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Chapter 2
Methods and Materials
2.1 FAM171B Amplification
PCR was conducted to amplify FAM171B cDNA from mouse cochlea to insert the
gene product in to a pGEM-T Easy vector. 12.5μl of Promega gotaq master mix (2X), 1μl
of appropriate primers (10mM) (Primer sequences shown in Figure 4, Appendix), 2μl of
DNA template (Cochlea cDNA) and 8.5μl H2O were mixed. Reaction PCR cycle ran in
95°C for 2 min, 95°C for 30sec, 55°C for 30 sec. Reaction was extended at 72°C for 1 min.
This reaction was repeated for 30 cycles. Reaction was then kept in 72°C for 5 min and
stored at 4°C.
PCR products were analyzed by agarose gel electrophoresis (Figure 1, Results) and
sent for sequence verification (Appendix, Figure 5 and 6). PCR clean-up was performed
accordingly to manufacturer instructions (Quiagen). In short, pH should be less than 7.5
for PCR purification. Buffer PB, DNA and pH indicator was added to the spin column.
Supernatant was discarded after centrifuging at 16000xg for 1 min. Buffer PE (750μl) was
added to the spin column and centrifuged for 1 min. The microcentrifuge tube was replaced
after another 1min centrifuge and supernatant was discarded. 30μl of the eluting buffer
was added to the spin column with DNA and incubate 1min. Flow through was collected
after 1 min centrifugation.
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2.2 Gel Confirmation of FAM171B Insert Generation
1% Agarose gel was made using 0.6g of Agarose in 60ml of 1% TAE buffer and
by adding 1.2μl Ethidium Bromide. 2μl of 6X-loading dye was added to the prepared 10μl
DNA samples. 12μl of 1Kb bio-life DNA ladder (NEB) was inserted to the 1 st well of the
gel. Gel electrophoresis was conducted in 96V for 45 Min (Figure 1, Results).
2.3 Sub-clone FAM171B into a pGEM-T Easy Vector
TA cloning was performed using 7.5μl 2X rapid ligase buffer, 1 μg pGEM-T Easy
vector, 0.5μl PCR product (DNA insert), 1.5μl T4 DNA ligase was mixed in micro
centrifuge tubes and stored at 4°C overnight. (Appendix figure, 1)
2.4 Transformation
LB/Ampicillin/ IPTG/X-Gal plates were prepared. Ligation reaction mixture was
centrifuged and 1.5μl of each ligation reaction was added to a sterile 1.5ml tube. JM109L2005 high efficiency competent cells were placed in an ice bath until just thawed (5min).
Cells were mixed by gently flicking the tube and 25μl of cells were transferred to the
ligation reaction tubes. Mixture was gently mixed and incubated on ice for 30mins. Cells
were heat-shocked for 25 Sec in a water bath at 42°C. Tubes were then immediately
returned to the ice for 2 min. 450μl of room temperature LB medium was added to the
ligation reaction transformation and incubated for 60mins at 37°C.

100μl of each

transformation culture was then added to LB/Ampicillin/IPTG/X-Gal plates. Plates were
incubated overnight at 37°C, and only the white colonies were selected (Figure 2,
Appendix).
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5ml of LB broth and 5μl of ampicillin were mixed to make liquid bacterial cultures.
One isolated white colony was inserted to the mixture and incubated at 37°C for 18 hrs.
For glycerol stocks, 1ml of culture was added to the 1.5 ml storage tubes and bacteria were
pelleted. 25% glycerol and fresh LB broth was added to the tube, and glycerol stocks were
stored at -80°C.
2.5 Isolating the vector with FAM171B gene
A quiagen mini-prep was used to isolate pGEM T-easy vector containing
FAM171B according to manufacturer instructions. In short, 1 ml of overnight cultures
were centrifuged and LB broth was decanted. Pelleted cells were re-suspended in 250μl
buffer P1, and transferred to a new tube. 250μl buffer P2 was added and the tube was mixed
thoroughly by inverting 4-6 times. 350μl buffer N3 was added and mixed immediately by
inverting the tube 4-6 times. The mixture was centrifuged for 10min at 16,000xg.
Supernatant was applied to the QIAprep spin column and centrifuged for 60sec, and the
flow through was discarded. 0.5ml of wash buffer PB was added to filter, centrifuged for
60sec, and the flow through was discarded. 0.75 ml buffer PE was added as a wash buffer,
centrifuged for 60sec, and the flow through was discarded. The mixture was centrifuge for
additional 1min to remove residual wash buffer. To elute the DNA, the QIA prep column
was placed in a clean 1.5 ml micro centrifuge tube, 50μl buffer EB was added to the center
of each QIAprep spin column and centrifuged for 1 min.
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2.6 Confirmation of Probe
Restriction Digest using NotI
NotI restriction enzyme (NEB) was used to cut the plasmid from SP6 and T7
promoter regions and to isolate the gene product (800bp). This step was performed to
confirm that the plasmid contains FAM171B gene. Restriction digest was performed by
adding 5μl of 10X BSA buffer, 300μg mini-prep DNA template, 5μl 10X NEB 3.1 buffer,
5μl NotI, 25μl of H2O, and the reaction digested overnight at 37°C. Appendix figure 3
shows the confirmation of FAM171B after Restriction digest with NotI.
After restriction digest using NotI, DNA samples were sent for sequencing (Genewiz) and
sequencing data confirmed FAM171B DNA insert (Appendix figure 5 and 6).
2.7 Linearization of FAM171B vector for Probe Generation
Restriction Digest ApaI (50μl) reaction
Restriction Digest at Sp6 promoter region of pGEM T-Easy vector was conducted
using ApaI restriction enzyme. 5.6μg of DNA template, 2μl of ApaI (NEB), 5μl of Cut
smart buffer (10x) and H2O (up to 50μl) were mixed in a 1.5 micro-centrifuge tube and
incubated at 25°C for overnight.
Restriction Digest using SalI 50μl reaction
Restriction Digest at T7 promoter region of pGEM T-Easy vector was conducted
using SalI restriction enzyme. 5.6μg of DNA template, 2μl of Sal1 (NEB), 5μl of Buffer
3.1(10X) and H2O (up to 50μl) were mixed in a 1.5ml tube. The reaction mixture was
digested overnight at 37°C.
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Agarose gel electrophoresis was performed on a small portion (4μl) of restriction
reactions to confirm plasmids were fully cut with SalI and ApaI restriction enzymes
(Appendix Figure 7). The rest of the restriction reaction (46μl) was then purified using a
QIAquick cleanup kit. In short, 230μl of PB was added to 46μl of restriction mix. The
reaction mixture was then placed to the QIA column and centrifuged for 60sec. After
discarding the flow through, 750μl of buffer PE was added to the QIA quick column,
centrifuged for 1 min, the flow through was discarded, and the column centrifuged for
another 1min. To elute DNA, the QIAquick column was placed in a clean 2ml collection
tube, 30μl buffer EB was added, and allowed to stand for 1min and eluate was collected by
centrifugation. FAM171B purified digests were stored at -20ºC.
2.8 In-vitro RNA Transcription Reaction
RNA transcription was performed by adding DNA template (2µg), 5x transcription
buffer (5.0 µl), 10mM DIG NTP mix (2.5 µl), RNAse inhibitor (1.0µl) and RNA
polymerase SP6 or T7 (5.0 µl); water was added to adjust the final volume to 50µl. The
solution containing DNA was then incubated at 37ºC for 2 hours. 2 µl of DNaseI (RNAse
free) was added to the solution and incubated for 1 hour at 37ºC. A portion of the samples
were then electrophoresed on 1% agarose gel in 1xTAE to confirm the presence of RNA
probe, and that the DNA plasmid had been completely digested (Appendix Figure 8).
SP6 and T7 promotor regions of the pGEM-T Easy vector and ApaI and SalI
restriction enzymes were used to generate FAM171B experimental (Antisense) and
FAM171B control (Sense) probes. Orientation of FAM171B was determined by DNA
sequencing data (Appendix Figure 5 and 6). Thus, mRNA transcribed after vector cut at
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SP6 promotor region was chosen as the antisense (Experimental) probe and mRNA
transcribed after vector cut at T7 promotor region was chosen as the sense (Control) probe
(Appendix Figure 6).
Fragmenting RNA Probe:
A heat block was set at 60ºC. 50 µl of 0.2M Na2CO3 and 50 µl of 0.2M NaHCO3
(final pH=10.2) was mixed to make hydrolysis buffer. 100µl of the probe was then added
to 100µl hydrolysis buffer and the mixture was incubated at 60ºC for 10min and placed on
ice.
To precipitate the RNA, 30 µl 2M Na acetate (pH=6.0) and 2.5 vol of 100% ethanol
was added to each sample with each probe and incubated at -80ºC for an hour. The reaction
was vortexed and centrifuged at 16000xg for 30 min at 4ºC and ethanol was decanted. The
precipitated RNA was then washed with 1 ml of 70% ethanol. Reaction was then
centrifuged at 16000xg for 10 min at 4ºC and the pellet dried. The pellet was then resuspended in 50µl high molecular grade H2O. The concentration was measured using the
Nano-drop and the probe re-suspended at 20ng/µl in Hybridization buffer.
2.9 Mice Brains
C57BL/6 mice colonies were reared (IRB: 15-02), and brain tissues were dissected
from male mice of 4 different age groups: p7, p21, p42, and 6 months. Brains were snap
frozen in liquid nitrogen and stored at -80C until further processing. Frozen brains were
sliced using a cryostat, and 12um sections were deposited onto charged glass slides (Fisher
labs). Adult mouse brains were approximately 8mm wide. Since this study focused on the
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left side of the brain, and sagittal brain sections were collected every 100 microns, each
adult mouse brain produced ~40 sections.
These thin sections of mouse tissue (that theoretically contain FAM171B) were
then probed for indications of FAM171B mRNA expression.
2.10 In-situ Hybridization for Mice Brain Tissues
Day 1
Pre-hybridization.
Slides containing brain sections were fixed in 4% PFA / 1x DEPC-Tx PBS for
10min, and washed twice in 1x DEPC-Tx PBS for 2 min.
Tissue slices were acetylated in 0.1M TEA/0.25% Acetic Anhydride 10min. Next,
tissues were permeablilized in 0.1% Triton X-100/PBS at RT for 10 min, and washed 3X
with 1x DEPC-Tx PBS for 2 min using coplin jars.

Slides were transferred to a

hybridization chamber and 500 µl of hybridization buffer (20ml of formamide, 8ml of 20X
SSC, 0.8ml 50X Denhardts reagent, 8ml of 50% Dextran sulfate, 1.2ml DEPC water, 2ml
of fish sperm DNA) was added to the slides and incubated at room temp 2 hr. Probe
dilutions were made in hybridization buffer. To make 500ng/mL of probe, 125μl of 20ng/μl
stock probe was mixed with 5ml of Hybridization buffer. Probe was then heated at 80ºC
5min to denature. Hybridization buffer already on the slides was removed and 250µl
diluted probe was then added to slides, and cover-slipped. Slides were hybridized overnight
at 57ºC after slides were placed in a tray containing paper towels moistened with 50%
formamide/0.2X SSC.
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Day 2
Post hybridization
Coverslips were removed by allowing them to slide off while in 1x SSC buffer.
0.2xSSC was used to wash slides 4 times with 15mins intervals for 1 hr. at 68-72ºC in
Coplin jars. Slides were then allowed to cool to room temperature, and washed with fresh
RT 0.2xSSC for 5min.
Antibody and alkaline phosphatase detection with BCIP/NBT
Slides were washed in maleic acid buffer (MB) for 5min at room temperature. MB
was removed and 30ml of 2% MBMB was added at RT for 1 hr. This blocking buffer was
prepared by diluting 10% MBMB (Roche) 1x maleic acid buffer. Slides were removed
individually and placed on the humidified chamber and covered with 500μl antiDigoxygenin-AP antibody (Roche) diluted 1:2000 in 2% MBMB. Slides were incubated at
room temperature for overnight.
Day 3
Post-antibody wash
Slides were washed in MB for 30 min at room temp in Coplin jar. Then slides
washed in color reaction buffer (100ml 0.5M Tris pH 9.5, 10ml 5M NaCl, 2.5ml of 1M
MgCl2, 50µl Tween 20, and 387ml H2O) for 30min. NBT/BCIP color reaction solution was
made by mixing 200ul NBT/BCIP stock and 10 ml of color reaction buffer. 500 µl of
NBT/BCIP color reaction mixture was added to each slide. Slides were incubated on a tray
with dampened paper towels, covered in aluminum foil, and incubated 7 hours.
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Day 4
Mount slides
Slides were washed 1xPBS for 5min at room temperature, and mounted using
Aqua/Polymount (Polysciences). Once dry, slides were stored in at room temperature.

2.11 Analyzing microscopic slides and densitometry
After each in-situ, microscopic slides with mice brain sections were analyzed using
a ZEISS Axiostar plus compound light microscope. Pictures of the experimental brain
regions and control brain sections were taken using a progress C10 plus camera connected
to the Axiostar plus compound light microscope.
Densitometry was used to conduct the semi-quantitative analysis of the expression
of FAM171B in different regions of the mouse brain. Two main brain regions
(hippocampus and cerebellum) were selected based on the highest expression of
FAM171B. ImageJ-NIH software was used to convert each image to 8-bit to get a grey
scale picture. In each microscopic picture, the chosen brain region with the FAM171B
expression was highlighted and selected using the “analyze” tool. Expression of FAM171B
in each experimental brain region was measured and background stain (from nearby
“white/non-stained” region in same image) was subtracted from original experimental
measurement. Control brain images (stained with “control” probe) from corresponding
regions were obtained and measured in an analogous fashion. The control brain
measurements were then subtracted from the measurement obtained from the experimental
brain region, and the results plotted in bar graph format.
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2.12 Statistics
Three mouse brains were collected for each age group (N=3), and each brain was
micro-sectioned into 12 um sagittal brain sections. From each brain, ~40 brain sections
were obtained for the experimental probe, and 10 brain sections were obtained for the
control probe. Thus, after three in-situ experiments, 120 brain sections per age group were
analyzed both semi-quantitatively and qualitatively and compared to 30 control brain
sections per each age group. Specifically, this analysis was performed by measuring
FAM171B expression (in Ammon’s horn, Dentate gyrus, and cerebellum) in all
experimental brain sections via densitometry (described above) ensuring that, the
background staining of this region of the control samples was subtracted from the
expression observed in experimental brain sections. Once the background was removed,
and the expression level determined, the relative FAM171B expression of other age groups
was normalized to P7. A univariate ANOVA test was then performed to determine whether
or not the level of FAM171B expression was significantly different amongst the 4 age
groups.
2.13 Qualitative study
A qualitative study was performed by observing the expression of FAM171BmRNA throughout the brain, specifically focusing on the Hippocampus, Cerebellum,
Cortex, Amygdala, Thalamus, Caudate and Corpus callosum. For this part of the study, a
compound microscope was utilized to examine the respective brain regions, and a
qualitative score was ascribed for each region by visually comparing the experimental
signal versus the control signal. Expression levels were assigned as follows: high signal
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(+++), medium signal (++), low signal (+), and no signal (-). For this part of the study, 120
experimental brain sections per age group were compared against 30 brain sections per age
group.
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Chapter 3
Results

3.1 Confirmation of FAM171B in Mouse Cochlea
FAM171B DNA was sucessfully amplified using mouse cochlear DNA as the
cDNA template. Electrophoresis and subsequent comparison to a 1 kb DNA ladder (Lane
1) illustrate the presence of the desired 800bp fragment (Lanes 2 and 3). DNA sequence
confirmed the PCR fragment was indeed FAM171B (Figure 6, Appendix). These results
strongly suggest that FAM171B is indeed expressed, at the mRNA level, in mouse.
1KB MW FAM171B FAM171B

1000bp

500bp

Figure 1. Gel electrophoresis analysis confirming the presence of FAM171B in mouse
cochlea. 1kb DNA ladder on the first lane. FAM171B DNA bands on the second and
third lane.
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3.2 FAM171B mRNA expression in mouse brain
In-situ hybridization strongly suggests that, FAM171B mRNA is expressed widely
in mouse brain (Figure 2). In this figure, the presence of the purple color throughout the
brain tissue confirms the expression of FAM171B at the mRNA level after performing an
in-situ hybridization using the experimental probe. Even though, FAM171B is expressed
throughout the majority of the brain, expression is more prominent (denoted by the darker
purple color) in specific regions of the brain including the hippocampus, cortex,
cerebellum, thalamus, caudate and amygdala (Figure 2).

Figure 2. Sagittal brain section of a 21-day-old male mouse after performing in-situ
hybridization with the experimental FAM171B mRNA probe. The image was obtained
using a dissecting microscope on 10X magnification. HIPP correspond to the
hippocampus, CTX stands for cortex, CRBL stands for cerebellum, THAL stands for
thalamus, CN stands for caudate, and AMYG stands for amygdala.
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3.3 Qualitative Analysis of FAM171B mRNA in mouse brain
Qualitative analysis of the different regions of the mice brains confirmed a high
level of FAM171B mRNA expression in all four age groups examined (Table 1). As
anticipated, FAM171B was expressed throughout the mice brains of the experimental
group as compared to those sections hybridized with the control probe, which revealed no
expression. Although FAM171B mRNA expression was widespread in the brains of all 4
age groups, much higher levels of expression were observed in the following regions:
Dentate gyrus and Ammon’s horn of the hippocampus, Purkinje cell layer and granular
layer of the cerebellum, motor and sensory cortices, amygdala, thalamus and the caudate.
Interestingly, expression of FAM171B was absent in the the white matter of the brain, such
as Corpus callosum.
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Table 1. Qualitative analysis of the expression of FAM171B mRNA in the different
regions of the brains of mice belonging to different age groups after performing an in-situ
hybridization. The +++ indicates the highest degree of expression, ++, moderate
expression, +, low expression, and –, no expression.
P7

P21

P42

6M

Brain Structures

Experimental

Experimental

Experimental

Experimental

Ammons Horn

+++

+++

+++

++

Dentate Gyrus

+++

+++

+++

++

Caudate

++

++

+

++

Cerebellum

++

++

+

+

Thalamus

++

++

+

++

Amygdala

++

++

+

++

Corpus Callosum

-

-

-

-

Motor Cortex

++

+++

++

++

Sensory Cortex

++

+++

++

++
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3.4 Detection of FAM171B mRNA Expression in Hippocampus
Figure 3, illustrates FAM171B expression in the hippocampus of mice brains
hybridized with the experimental (top panel) and control (bottom panel) probe. These data
clearly indicate that FAM171B mRNA is strongly expressed in the hippocampus. All of
the mice brains within the experimental group, regardless of age, exhibit a dark purple
color following performance of the in-situ hybridization which suggests that FAM171B
mRNA is highly expressed in this region. Control mice brains, on the other hand, (treated
with a control FAM171B probe that contains the same exact mRNA sequence as the
mRNA present in mice brain tissues), displays little to no purple color after performing the
in-situ hybridization (Figure 3).

Experimental

Control

Figure 3. FAM171B expression in the hippocampus of 7-day, 21-day, 42-day, and 6month-old mice. The image was observed using the 5X objective of a compound
microscope.
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Figure 4 illustrates prominent expression of FAM171B mRNA in the
hippocampus of a sagittal brain section of a 21-day-old mouse model. This figure was
captured after performing an in-situ hybridization of mice tissue using the experimental
probe. The dark purple color indicates that FAM171B is highly expressed in both the
Dentate Gyrus and the Ammon’s Horn regions of the hippocampus.

Figure 4. FAM171B expression in the Dentate Gyrus and the Ammon’s Horn regions of
the hippocampus of a 21-day-old mouse sagittal brain section hybridized with the
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experimental probe. This image was observed using the 5X objective lens of a compound
microscope.
Semi-quantitative analysis also indicates that FAM171B mRNA is highly
expressed in the Ammon’s Horn region of hippocampus of 7-day, 21-day, 42-day, and 6month old mice brains hybridized with the experimental probe (Figure 5). A univariate
ANOVA test displayed a P value (P = 0.573) suggesting that the expression of FAM171B
is not significantly different amongst the four age groups.

F =0.613, P=0.573

160

2,6

Relative FAM171B % normalized to P7

140

120
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P21

P42

6M

Age Group

Figure 5. Semi-Quantitative analysis of FAM171B expression in Ammon’s Horn region
of the hippocampus in mice brains of four different age groups.
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Like Ammon’s Horn, FAM171B mRNA is also highly expressed in the Dentate
Gyrus region of the hippocampus of experimental mice brains across all four age groups
(Figure 6). A univariate ANOVA test displayed a P-value of 0.108, which suggests no
significant difference in FAM171B expression amongst the different age groups.
200

F =3.303, P=0.108

Relative % of FAM171B expression normalized to P7

2,6

P=0.125

180

160
140
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20
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P21

P42

6M

Age Groups

Figure 6. Semi-quantitative analysis of FAM171B expression in the Dentate Gyrus region
of the hippocampus of mice brains belonging to different age groups.
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3.5 Detection of FAM171B mRNA expression in the Cerebellum
The dark purple staining in Figure 7 and 8 indicates that FAM171B mRNA is
expressed in the cerebellum of an adult mouse brain. Upon closer inspection, it is clear that
FAM171B mRNA expression is prominent in the Purkinje cell and granular cell layers,
and the lowest in the molecular layer (Figure 8).

Figure 7. FAM171B mRNA expression in the cerebellum of a 6-month-old mouse brain
treated with the experimental probe during in-situ hybridization. Images were obtained
using the 5X (a) and 40 X (b) objectives of a compound microscope.
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Experimental

Control

Figure 8. Qualitative analysis of FAM171B expression in cerebellum of mice brains in
different age groups treated with experimental probe during in-situ hybridization compared
to brains treated with control probe. Pictures were taken at 5X objective under compound
microscope.
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The one-way ANOVA test performed, based on the results of the densitometry
(after normalization of the relative percent expression to P7), yielded a P value of P =
0.440, suggesting that FAM171B expression in the cerebellum is not significantly different
amongst the 4 different age groups (Figure 9).

Relative % expression of FAM171B normalized to P7

180

F
160
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= 0.946, P=0.440
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Figure 9. Semi-Quantitative analysis of FAM171B expression on cerebellum in mice
brains correspond to different age groups.
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Chapter 4
Discussion
FAM171B is an uncharacterized novel protein that contains polyglutamine
residues within its amino acid sequence. Given the homology that is shares with proteins
that result from mutated genes associated with polyglutamine diseases, FAM171B may
also be linked to one or more neurodegenerative polyglutamine (polyQ) diseases.
Unfortunately, the location or function of FAM171B is unknown, thus the current study
was undertaken to localize the expression of FAM171B in mouse brains. Mice were
selected as the model to study FAM171B because genomic sequence data shows that they
are known carriers of the FAM171B protein. Moreover, the mouse FAM171B protein has
88% homology with the human FAM171B protein and contains ~7 glutamine repeats
(humans have ~ 16 repeats) (39).
The goal of the present study was to localize FAM171B mRNA in mice brains
representing 4 different age groups (7-day (P7), 21-day (P21), 42-day (P42) and 6-month
old (6M) mice) using in-situ hybridization. The data collected indicates that FAM171B
mRNA is expressed widely throughout mice brains, regardless of age. However, upon
closer examination of each brain section, it was observed that FAM171B expression is
more prominent in some brain regions than others (Figure 2, Table 1). Densitometry data
indicated there is no significant difference in expression of FAM171B mRNA among age
groups, however since densitometry does not precisely measure the level of FAM171BmRNA expression, we consider this analysis as a semi quantitative analysis.
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Qualitative analyses reveal that, of all the brain regions examined, the
hippocampus seemed to exhibit the highest level of FAM171B mRNA expression (Table
1). The hippocampus, which is a part of the limbic system and is located in the temporal
lobe of the cerebral cortex, is an essential neuronal structure, responsible for playing a key
role in consolidation of information from short term memory into long time memory. This
structure is also responsible for storing and processing spatial memory that helps with
navigation, with the dorsal portion being responsible for learning and forming memories
(especially spatial navigation), and the ventral section primarily involved with anxiety
associated behavior (26). Many polyglutamine neurodegenerative disorders (e.g.,
Huntington’s disease and Spinocerebellar Ataxia), result in impaired memory and
dementia, which may be due to the impaired hippocampus functioning (38). Consequently,
the expression of FAM171B mRNA in the hippocampus may suggest that this
polyglutamine protein is linked to an underlying neurodegenerative disorder.
A high level of FAM171B mRNA expression was also observed in the cerebellum,
the main structural feature of the hind-brain. Qualitative as well as semi-quantitative
analyses confirm that FAM171B mRNA is highly expressed in this region of the brain
(Figures 7, 8 and 9). The cerebellum is known to play a vital role in attention, language,
emotional responses, addiction, pain, working memory, learning and pain (36). Planning
and execution of movements or motor control is another important function of the
cerebellum in humans (27), although it should be noted that this structure does not initiate
movements but is responsible for muscle coordination, precision and precise timing.
Structurally, the cerebellum is divided in to three main layers: (1) the molecular, (2)
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granular layer and (3) Purkinje cell layers. Of these, the granular layer is the deepest,
consisting of densely packed granule cells (the smallest and most numerous neurons in the
brain), Golgi cells also known as inhibitory interneurons, unipolar brush cells (excitatory
glutamatergic interneurons), and Lugaro cells, sensory interneurons that performs
inhibitory functions. The middle narrow layer consists of Purkinje cells, the most
distinctive neurons in the brain that are typically recognized by the shape of their dendritic
tree that branches profusely. Because Purkinje cells use GABA as neurotransmitter, they
exert inhibitory effects on their target(s). Finally, the molecular layer, the outermost layer
of the cerebellum, contains basket and stellate cells, both of which are inhibitory
interneurons that forms GABAergic synapses with the dendrites of Purkinje cells. Of these
3 layers, qualitative study indicates that the Purkinje cell and granular layers have the most
prominent FAM171B mRNA expression in mice brains of all 4 age groups (Figure 9)
although this expression is not significantly different among the different age groups. This
finding suggests that FAM171B mRNA is present though out brain development of the
mice.
In many polyglutamine neurodegenerative disorders the cerebellum is the region of
the brain that is impaired. According to Orr (28), Purkinje cells in the cerebellum are
severely affected/lost in persons/mice afflicted with spinocerebellar ataxia type 1 (SCA
type 1) because of the expanded number (~77) of glutamine residues in the SCA-1 gene
product that produces the ataxin-1 protein and, consequently, ataxia. Studies by the above
author (28) as well as Paulson et al., (12) suggest that overexpression of glutamine residues
in the SCA3 gene in transgenic mice results rapid cell loss of Purkinje cells, leading to
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cerebellar atrophy and ataxia. Moreover, SCA6 (spinocerebellar ataxia type 6), like SCA1,
results in severe cell loss in the Purkinje cell layer of the cerebellum. It is very likely that
Purkinje cell death in persons with SCA6 is caused by having an excess entry of calcium
into the Purkinje cells because of the SCA 6 gene mutation (28). Finally, SCA type 17,
Dentatorubral and pallidoluysian atrophy (DRPLA) and Huntington’s disease, other
polyglutamine diseases caused by having an expanded number of CAG repeats within the
mutated gene, results in severe alterations/degeneration in the cerebellum (16) (17) (29)
(37). Given that FAM171B protein also contains polyglutamine repeats within its amino
acid sequence and is highly expressed in the neuronal layers of the cerebellum (i.e., the
Purkinje cell and granule cell layers) throughout development of the brain, this protein may
have an underlying relationship with one or more polyglutamine disorders.
Our data also shows that the caudate is another region of the brain that FAM171B
mRNA is expressed in. Qualitative analysis of the results of the in-situ hybridization
indicates that there is moderate expression of FAM171B mRNA in the caudate of mice
models representing all 4 of the age groups (Table 1). This region of the brain is known to
play a vital role as a feed-back processor where it uses the information from past experience
to impact future actions and is also responsible for successful goal directed actions (30). In
addition, the striatum, which is composed of both the caudate and the putamen, is
responsible for multiple features of cognition including planning, motivation and decision
making (30). According to Orr (28), the pathology of Huntington’s disease, which impairs
most brain regions, results primarily from atrophy of the striatum, leading to a loss of
GABA mediated neurons in this region. The same author also reports that neuronal loss,
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specifically in striatum, hippocampus, thalamus and cortex, was observed in transgenic
mice that expressed full length Huntington’s disease cDNA. However, the investigators of
the abovementioned study concluded that the severity of Huntington’s disease depended
upon the length of the polyglutamine tract, the level of the expression of the transgene in
mice models and on the protein and the location of polyglutamine tract (28). Given these
findings, the observation of FAM171B expression in the caudate in all age groups
examined seems fascinating and may suggest a link to an underlying polyglutamine
disorder since FAM171B has homology with genes associated with known polyglutamine
disorders.
The cerebral cortex, the region of the brain that covers the outer portion of the
cerebrum, consists of many folded regions called gyri that increase the surface area of the
brain and thus the amount of information that can be processed by the brain (32). This
portion of the brain is responsible for many functions including motor movements,
planning and organization, intelligence and personality determination, and the processing
of language and sensory information (32). Damage to the cortex often results in ataxia,
which is characterized by a lack of muscle coordination and balance. Ataxia is the most
profound symptom of several types of spinocerebellar ataxias (SCA1, SCA3, SCA6,
SCA17 and DRPLA) all of which are classified as polyglutamine neurodegenerative
disorders. Although the cortex is affected in these above disorders, the pattern of
degeneration and the relationship of cortical degeneration to the clinical symptoms can be
difficult to assess due to the complex folding pattern of the cortex (28). Given the
association of cortex damage and polyglutamine neurodegenerative disorders, it is not
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surprising that in the present study, the cortex was found to express moderate levels of
FAM171B mRNA among all age groups examined, with the most prominent expression
observed in both the motor and sensory cortices.
The thalamus, the brain’s relay center, is located below the corpus callosum of the
brain and is considered a part of the forebrain. The thalamus is primarily responsible for
conveying information from the sensory receptors to the appropriate region of the brain
where the sensory information can be processed (28). As mentioned previously, neuronal
loss in thalamus, among other areas of the brain, was observed in transgenic mice
expressing full length Huntington’s disease cDNA (28). In addition, another study that
mapped the MRI data of several Huntington’s disease patients revealed that both striatal
and thalamic atrophy was prominent among this group (33). Therefore, the observation of
moderate levels of FAM171B mRNA in the thalamus of mice models in all 4 age groups
is intriguing.
The amygdala, like the thalamus, exhibited moderate expression of FAM171B
among all 4 age groups. This portion of the brain is located within the temporal lobes and
is a part of a limbic system. The amygdala plays an important role in processing emotions
such as anger, fear and pleasure (34) and also determines what memories are stored and
where in the brain they are stored. Neurodevelopmental disorders such as Williams
syndrome, Schizophrenia, anxiety and autism (34) are all known to affect the amygdala.
PolyQ disorders, in contrast, do not routinely impair this part of the brain, although various
levels of Amygdala neurodegeneration have been reported in some Huntington’s disease
patients (35).
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The Corpus callosum, the large bands of white matter that do not have neuronal cell
bodies, but connect the left and right hemispheres of the cerebrum, is involved in
communication among the different parts of the brain. Qualitative analysis indicates that
FAM171B mRNA is not expressed in this region of the brain in any of the 4 age groups
examined. These data indicate that FAM171B may only be expressed in neuronal cell
bodies (grey matter), but not in the white matter. Furthermore, additional research is needed
to determine whether FAM171B is also expressed in glial cells such as astrocytes and
microglia.

39
Chapter 5
Conclusion
FAM171B is a novel protein that possesses a number of polyglutamine tracts (7 in
mice vs. 16 in humans) but its function remains relatively unexplored. Sequence analysis
of FAM171B, however, reveals that this protein shares some homology with other altered
proteins involved in polyglutamine neurodegenerative disorders. Thus, the present study
was preformed to examine expression levels of FAM171B mRNA in different regions of
mice brains representing 4 different age groups (7-day-, 21-day-, 42-day- and 6-month-old
mice). Our findings indicate that although FAM171B mRNA is widely expressed in the
brains of mice belonging to each age group, discernable differences in expression were
apparent in the hippocampus, cerebellum, cortex, amygdala and thalamus. Our data also
indicates that FAM171B mRNA is not expressed in the Corpus callosum, the large tracts
of white matter between the left and right cerebral hemispheres, suggesting that FAM171B
is most likely expressed only in neuronal cell bodies. In addition, the results of this study
indicate that FAM171B mRNA expression is consistent among the 4 different age groups,
implying that FAM171B is probably present in mice brains throughout their development.
Given that FAM171B, like other polyQ proteins, contains a polyglutamine stretch and has
high expression levels in the aforementioned brain regions, this protein may have an
underlying role in one or more polyglutamine neurodegenerative disorders that have yet to
be molecularly characterized. Future work includes examining FAM171B protein levels
and expression patterns via immunohistochemistry, and investigating the intracellular
expression of FAM171B using immunofluorescence techniques.
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Appendix

7.1 pGEM-T Easy vector properties

Figure 1: pGEM-T Easy vector map (www.promega.com)
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7.2 Transformation of Vector to JM109 Bacteria

Figure 2. Transformation of pGEM-T Easy vector to JM109 bacteria. Blue colonies
indicate transformed vectors without the FAM171B insert. White colonies Indicate
transformed vectors with FAM171B insert.

Figure 2 contains JM109 bacterial colonies after transformed with pGEMT-Easy
vector. These bacteria were grown in a media with ampicillin. Therefore, all these bacteria
that grew in this specific media transformed the pGEM-T Easy vector because vector itself corresponded with ampicillin resistance. Since X-gal was also added to this media, it
can recognize Lac-Z marker on the vector and change the color of the bacteria to blue color,
if that marker was not interrupted by an insert in between. Therefore, bacterial colonies
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that were colored in blue in this figure contains the pGEM-T Easy vector but not the
FAM171B insert and white colonies contain the pGEM-T Easy vector with the FAM171B
fragment.

7.3 Confirmation of Restriction Digest with NotI

Figure 3. Gel electrophoresis analysis confirming restriction digest of the vector with
NotI enzyme. 1kb DNA ladder on the first lane. Uncut pGEM-T Easy vector with
FAM171B on the second lane . pGEM-T Easy vector(3000bp) and FAM171B fragment
(800bp) after restriction digest with NotI on the third lane.
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Figure 3 indicates gel electrophoresis analysis of restriction digest of the pGEM-T
Easy vector using NotI restriction enzyme. This procedure is only conducted to confirm
to see if the vector contains the desired FAM171B fragment. NotI enzyme cuts at both
SP6 and T7 promotor regions of the vector allowing to isolate the FAM171B fragment.
Therefore, when pGEM-T Easy vector cut with NotI, we should be able to see two bands
on the gel, one band corresponds to the size of the vector which is 3000bp and the other
band corresponds to the size of the FAM171B, which is 800bp. Looking at two bands
appeared on lane C of the figure 3 and by comparing to the size of the bands to the DNA
ladder confirms that FAM171B is in the vector. This data was also confirmed by DNA
sequencing.
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7.5 Primers used for Fam171B amplification

Figure 4: Primers used in FAM171B amplification
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7.4 DNA sequencing data for FAM171B

Figure 5. DNA sequencing data for FAM171B on the SP6 Probe
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Figure 6. DNA Sequencing data for SP6 probe
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7.5 Restriction Digest with ApaI and SalI

Figure 7. Gel electrophoresis analysis of the Linearization of pGEM-T Easy vector using
ApaI and SalI restriction enzymes. 1kb DNA ladder on the first lane. pGEM-T Easy
vector cut with ApaI on the second lane . pGEM-T Easy vector cut with SalI on the third
lane.
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Figure 7 indicates the gel electrophoresis of restriction digest of pGEM-T Easy
vector using ApaI and SalI. ApaI restriction enzyme cuts at the sp6 promotor region of the
vector and salI restriction enzyme cuts at the T7 promotor regions of the vector.
Linearization is important because when we later conduct the in-vitro transcription of
FAM171B, linearization helps to avoid transcription of mRNA in a circular manner. ApaI
and SalI restriction enzymes helps to make control and experimental mRNA probes. Thus,
we know the direction of Fam171B after the DNA sequencing, vector cut with ApaI
identified as the experimental FAM171B contained plasmid and SalI, identified as the
control FAM171B contained vector.
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7.6 Confirmation of FAM171B mRNA after the transcription reaction

Figure 8. Gel electrophoresis analysis of In-vitro transcription of FAM171B mRNA. 1kb
DNA ladder (A). Experimental probe sp6 promotor region cut with ApaI without DNase
(B). Experimental probe sp6 promotor region cut with ApaI and DNase added (C). Control
probe T7 promotor region cut with SalI without DNase (D). Control probe T7 promotor
region cut with SalI and DNase added (E).

Figure 8 illustrates the in-vitro transcription of FAM171B using T7 and Sp6
promotor regions. Experimental and control FAM171B mRNA probes were prepared using
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ApaI and SalI restriction enzyme and by using SP6 and T7 promotor regions of the vectors.
These experimental and control probes were designed based on the orientation of
FAM171B DNA on mouse tissue from DNA sequencing data. Experimental FAM171B
mRNA probe will have the complementary mRNA sequence to the mRNA present in
mouse tissues whereas Control FAM171B mRNA probe will have the same sequence to
the mRNA present in the mouse tissue. In lane B and D, DNA bands corresponds to the
vector size present in both experimental and control probes due to not adding DNase. In
lane C and E DNA bands corresponds to the size of vector are not present in both control
and experimental probes in the gel due to addition of DNase. In lane C and E only the
mRNA bands can be visualized. Since these mRNA was single stranded, mRNA tends to
run in the gel in a distorted manner resulted creating various bands. FAM171B mRNA
experimental and control mRNA probes were present in figure 5 between 1000bp and
500bp band on the 1kb size standard. During this procedure, non-canonical DIG labeled
bases and DNase were added in to the reaction mixture.

